STALEY CAPITAL ADVISERS’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$57.2M Buy
2,035,654
+54,140
+3% +$1.44M 2.42% 16
2025
Q4
$49.3M Sell
1,981,514
-82,126
-4% -$2.07M 2.03% 16
2025
Q3
$52.6M Sell
2,063,640
-33,065
-2% -$816K 2.16% 15
2025
Q2
$50.8M Sell
2,096,705
-83,068
-4% -$1.94M 2.16% 15
2025
Q1
$55.2M Buy
2,179,773
+29,355
+1% +$768K 2.5% 13
2024
Q4
$57.1M Buy
2,150,418
+73,594
+4% +$2M 2.53% 12
2024
Q3
$60.1M Sell
2,076,824
-14,438
-0.7% -$421K 2.69% 12
2024
Q2
$58.5M Buy
2,091,262
+591,016
+39% +$16.3M 2.69% 12
2024
Q1
$41.6M Buy
1,500,246
+195,696
+15% +$5.43M 1.94% 17
2023
Q4
$37.6M Sell
1,304,550
-41,637
-3% -$1.26M 1.87% 18
2023
Q3
$44.7M Buy
1,346,187
+55,290
+4% +$1.96M 2.46% 13
2023
Q2
$47.4M Buy
1,290,897
+50,173
+4% +$1.95M 2.55% 12
2023
Q1
$50.6M Buy
1,240,724
+50,407
+4% +$2.18M 2.83% 12
2022
Q4
$61M Sell
1,190,317
-9,820
-0.8% -$471K 3.64% 9
2022
Q3
$52.5M Sell
1,200,137
-15,996
-1% -$777K 3.36% 8
2022
Q2
$63.8M Sell
1,216,133
-3,397
-0.3% -$173K 3.77% 6
2022
Q1
$63.1M Buy
1,219,530
+6,901
+0.6% +$358K 3.19% 9
2021
Q4
$71.6M Sell
1,212,629
-37,965
-3% -$1.88M 3.42% 7
2021
Q3
$53.8M Sell
1,250,594
-7,520
-0.6% -$333K 2.88% 9
2021
Q2
$49.3M Buy
1,258,114
+37,575
+3% +$1.46M 2.58% 13
2021
Q1
$44.2M Buy
1,220,539
+83,737
+7% +$2.97M 2.46% 13
2020
Q4
$41.8M Sell
1,136,802
-65,284
-5% -$2.39M 2.56% 13
2020
Q3
$41.9M Sell
1,202,086
-16,655
-1% -$584K 2.9% 9
2020
Q2
$37.8M Sell
1,218,741
-108,140
-8% -$3.67M 2.74% 9
2020
Q1
$41.1M Buy
1,326,881
+55,343
+4% +$1.89M 3.45% 7
2019
Q4
$47.3M Buy
1,271,538
+18,618
+1% +$663K 3.2% 7
2019
Q3
$42.7M Buy
1,252,920
+100,293
+9% +$3.65M 3.2% 9
2019
Q2
$47.4M Buy
1,152,627
+21,318
+2% +$847K 3.53% 7
2019
Q1
$45.6M Buy
1,131,309
+9,003
+0.8% +$361K 3.37% 9
2018
Q4
$46.5M Sell
1,122,306
-50,624
-4% -$2.1M 3.76% 4
2018
Q3
$49M Buy
1,172,930
+3,731
+0.3% +$144K 3.43% 9
2018
Q2
$40.2M Sell
1,169,199
-2,709
-0.2% -$92.6K 3.09% 11
2018
Q1
$39.5M Buy
1,171,908
+90,291
+8% +$3.1M 3.1% 11
2017
Q4
$37.2M Buy
1,081,617
+5,829
+0.5% +$199K 2.88% 11
2017
Q3
$36.4M Buy
1,075,788
+1,795
+0.2% +$57.7K 2.98% 11
2017
Q2
$34.2M Buy
1,073,993
+18,330
+2% +$578K 2.92% 10
2017
Q1
$34.3M Sell
1,055,663
-1,887
-0.2% -$59.5K 3.06% 11
2016
Q4
$32.6M Buy
1,057,550
+51,531
+5% +$1.57M 3.13% 10
2016
Q3
$32.3M Buy
1,006,019
+5,262
+0.5% +$176K 3.23% 9
2016
Q2
$33.4M Buy
1,000,757
+9,200
+0.9% +$294K 3.5% 7
2016
Q1
$27.9M Buy
991,557
+34,214
+4% +$977K 3.01% 9
2015
Q4
$29.3M Buy
957,343
+22,354
+2% +$703K 3.38% 8
2015
Q3
$27.9M Buy
934,989
+76,109
+9% +$2.44M 3.39% 7
2015
Q2
$27.3M Buy
858,880
+18,791
+2% +$612K 3.04% 9
2015
Q1
$27.7M Buy
840,089
+8,019
+1% +$255K 3.2% 6
2014
Q4
$24.6M Buy
832,070
+7,629
+0.9% +$219K 2.86% 11
2014
Q3
$23.1M Buy
824,441
+17,896
+2% +$502K 2.76% 12
2014
Q2
$22.7M Buy
806,545
+110,300
+16% +$3.14M 2.72% 10
2014
Q1
$21.2M Buy
696,245
+3,296
+0.5% +$98.3K 2.69% 11
2013
Q4
$20.1M Sell
692,949
-4,280
-0.6% -$125K 2.74% 11
2013
Q3
$19M Buy
697,229
+21,491
+3% +$585K 2.89% 9
2013
Q2
$18M Buy
+675,738
New +$18.7M 2.9% 9

Other funds holding PFE

STALEY CAPITAL ADVISERS's PFE Position: Q1 2026 in Review

STALEY CAPITAL ADVISERS increased its Pfizer (PFE) stake by 2.7% in Q1 2026, buying an estimated $1.44M and bringing the position to 2,035,654 shares worth $57.2M. The position accounts for 2.42% of the portfolio, ranked #16.

STALEY CAPITAL ADVISERS first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $71.6M in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • STALEY CAPITAL ADVISERS held 2,035,654 shares of Pfizer worth $57.2M as of Q1 2026.
  • STALEY CAPITAL ADVISERS bought 54,140 Pfizer shares in Q1 2026, an estimated $1.44M.
  • Pfizer made up 2.42% of STALEY CAPITAL ADVISERS's portfolio in Q1 2026, its #16 holding.
  • STALEY CAPITAL ADVISERS first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • STALEY CAPITAL ADVISERS's Pfizer position peaked at $71.6M in Q4 2021.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q1 2026, filed 29 Apr 2026.